This educational program consists of two components: a series of interactive, case-based lectures (10.50 AMA PRA Category 1 Credits™ available) and a Performance Improvement (PI)-CME activity (20 AMA PRA Category 1 Credits™ available).
Listen to up to 16 Lectures by Expert Faculty
Earn up to 10.50 CME Credits
Eligibility for CME credits for the lecture series has expired. Please print your CME certificates by May 3, 2013 as they will be unavailable after that date.
You may still review the educational materials without CME credit.
Join diabetes experts Mayer Davidson, MD, Alison Evert, MS, RD, CDE, M. Sue Kirkman, MD, Frank Lavernia, MD, Anne Peters, MD, Neil Skolnik, MD, and Craig Williams, PharmD, as they discuss a range of issues from solving the oldest problems to maximizing the newest solutions for patients with diabetes.
"This was THE best CME activity I have attended... You covered the
basics to the specifics in a way that pertains to the daily ins and outs of
caring for our most difficult patients. The conference also addressed so
many of our patients that are uninsured."
- Physician and Live Meeting participant, Los Angeles, CA
Participate in Performance Improvement
Earn up to 20 CME Credits
Assess your current practice against the ADA Standards of Medical Care in Diabetes—2011 and implement changes to make measurable improvements in the outcomes
of patients with diabetes.
"This PI CME activity has been so beneficial. I hope my Stage C results show that I improve. My baseline report is always on my mind as I see patients with diabetes."
"I feel my patients have very much benefitted from the knowledge I gained from this PI CME activity."
Participate in Performance Improvement - the "Core of the new CME"
- American Medical Association
This continuing medical education activity is sponsored by the American Diabetes Association.
This program is supported by unrestricted educational grants from Amylin Pharmaceuticals, Inc. and Lilly USA, Inc.; Bristol-Myers Squibb and AstraZeneca LP; Merck & Co., Inc; Merck/Schering-Plough Pharmaceuticals; and Genentech, a member of the Roche Group.